Fig 1: Association between the expression of FAP and immunosuppressive TME. (A) Representative images of IHC staining of FAP, macrophage M2 (CD163+), MDSC (CD11b+/CD33+) infiltration, and PD-1 expression in GC tissue microarrays. Scale bar = 100 µm. (B) Quantitative results of IHC for CD163, CD11b, CD33, and PD-1 in groups with low intensity and high intensity of FAP in GC tissue microarrays. * p < 0.05; ** p < 0.01; *** p < 0.001.
Fig 2: High expression of FAP indicates poor tumor prognosis. (A) FAP mRNA expression negatively correlates with response for ICB treatment in GC patients from Nanostring cohort (N = 48). (B) ROC curves measure the predictive value of FAP, PD-1, PD-L1, TIM3, and PDCD1LG2 in the Nanostring cohort (N = 48). The areas under the ROC curves are 0.733, 0.586, 0.709, 0.662, and 0.682 for the FAP, PD-1, PD-L1, TIM3, and PDCD1LG2, respectively. (C–E) FAP expression is negatively correlated with clinical outcome in a variety of tumors. In Kaplan-Meier analysis of the TCGA-STAD cohort (C), ACRG cohort (D), and IMvigor210 cohort (E), higher FAP expression indicates shorter overall survival.
Supplier Page from Abcam for Anti-PD1 antibody [EPR23119-111]